Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort

Journal of Diabetes and its Complications

Volumn 27, Issue 5, 2013, Pages 447-453

  Jenkins, Alicia J ^a   Yu, Jeremy ^a   Alaupovic, Petar ^b   Basu, Arpita ^c   Klein, Richard L ^d,e   Lopes Virella, Maria ^d,e   Baker, Nathaniel L ^d   Hunt, Kelly J ^d   Lackland, Daniel T ^d   Garvey, W Timothy ^f   Lyons, Timothy J ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Albuminuria; Apolipoproteins; Lipoproteins; Nephropathy; Type 1 diabetes

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN C3; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMINURIA; ARTICLE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; IMMUNOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INTENSIVE CARE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; WAIST HIP RATIO;

ALBUMINURIA; APOLIPOPROTEINS; LIPOPROTEINS; NEPHROPATHY; TYPE 1 DIABETES;

ADULT; ALBUMINURIA; APOLIPOPROTEINS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84883765452     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2013.06.002     Document Type: Article

References (48)

1. P. Alaupovic Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins Methods in Enzymology 263 1996 32 60
2. P. Alaupovic, J.M. Bard, M. Tavella, and D. Shafer Identification of apoB-containing lipoprotein families in NIDDM Diabetes 41 Suppl 2 1992 18 25
3. P. Alaupovic, H.N. Hodis, C. Knight-Gibson, W.J. Mack, L. LaBree, and L. Cashin-Hemphill Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS) Arteriosclerosis and Thrombosis 14 12 1994 1906 1913
4. P.O. Attman, P. Alaupovic, and A. Gustafson Serum apolipoprotein profile of patients with chronic renal failure Kidney International 32 3 1987 368 375
5. P.O. Attman, G. Nyberg, T. William-Olsson, C. Knight-Gibson, and P. Alaupovic Dyslipoproteinemia in diabetic renal failure Kidney International 42 6 1992 1381 1389
6. P.R. Blackett, K.S. Blevins, E. Quintana, M. Stoddart, W. Wang, and P. Alaupovic ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth Metabolism 54 2 2005 180 187
7. D.H. Blankenhorn, P. Alaupovic, E. Wickham, H.P. Chin, and S.P. Azen Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors Circulation 81 2 1990 470 476
8. D.C. Chan, M.M. Chen, E.M. Ooi, and G.F. Watts An ABC of apolipoprotein C-III: A clinically useful new cardiovascular risk factor? International Journal of Clinical Practice 62 5 2008 799 809
9. T.A. Chowdhury, P.H. Dyer, S. Kumar, S.P. Gibson, B.R. Rowe, and S.J. Davies Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM Diabetes 47 2 1998 278 280
10. V. Clavey, S. Lestavel-Delattre, C. Copin, J.M. Bard, and J.C. Fruchart Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E Arteriosclerosis, Thrombosis, and Vascular Biology 15 7 1995 963 971
11. L.K. Curtiss ApoE in atherosclerosis: A protein with multiple hats Arteriosclerosis, Thrombosis, and Vascular Biology 20 8 2000 1852 1853
12. T.M. Davis, R. Ting, J.D. Best, M.W. Donoghoe, P.L. Drury, and D.R. Sullivan Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2 2011 280 290
13. I.H. de Boer, T.C. Rue, P.A. Cleary, J.M. Lachin, M.E. Molitch, and M.W. Steffes Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort Archives of Internal Medicine 171 5 2011 412 420
14. I.H. de Boer, S.D. Sibley, B. Kestenbaum, J.N. Sampson, B. Young, and P.A. Cleary Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study Journal of the American Society of Nephrology 18 1 2007 235 243
15. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort Diabetes Care 22 1 1999 99 111
16. K.F. Hilpert, S.G. West, P.M. Kris-Etherton, K.D. Hecker, N.M. Simpson, and P. Alaupovic Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes American Journal of Clinical Nutrition 85 2 2007 369 376
17. P. Hovind, L. Tarnow, P. Rossing, B.R. Jensen, M. Graae, and I. Torp Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study BMJ 328 7448 2004 1105
18. A.A. Jaffa, W.R. Usinger, M.B. McHenry, M.A. Jaffa, S.R. Lipstiz, and D. Lackland Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes Journal of Clinical Endocrinology and Metabolism 93 5 2008 1893 1900
19. A.J. Jenkins, J.D. Best, R.L. Klein, and T.J. Lyons Lipoproteins, glycoxidation and diabetic angiopathy Diabetes/Metabolism Research and Reviews 20 5 2004 349 368
20. A.J. Jenkins, T.J. Lyons, D. Zheng, J.D. Otvos, D.T. Lackland, and D. McGee Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy Kidney International 64 3 2003 817 828
21. A.J. Jenkins, T.J. Lyons, D. Zheng, J.D. Otvos, D.T. Lackland, and D. McGee Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: Associations with gender and glycemia Diabetes Care 26 3 2003 810 818
22. A.J. Jenkins, K.G. Rowley, T.J. Lyons, J.D. Best, M.A. Hill, and R.L. Klein Lipoproteins and diabetic microvascular complications Current Pharmaceutical Design 10 27 2004 3395 3418
23. H.J. Kim, E.H. Cho, J.H. Yoo, P.K. Kim, J.S. Shin, and M.R. Kim Proteome analysis of serum from type 2 diabetics with nephropathy Journal of Proteome Research 6 2 2007 735 743
24. H. Kimura, Y. Suzuki, F. Gejyo, R. Karasawa, R. Miyazaki, and S. Suzuki Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM American Journal of Kidney Diseases 31 4 1998 666 673
25. R. Klein, B.E. Klein, S.E. Moss, K.J. Cruickshanks, and P.C. Brazy The 10-year incidence of renal insufficiency in people with type 1 diabetes Diabetes Care 22 5 1999 743 751
26. R.L. Klein, M.B. McHenry, K.H. Lok, S.J. Hunter, N.A. Le, and A.J. Jenkins Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort Journal of Diabetes and its Complications 19 1 2005 18 25
27. D.M. Lee, C. Knight-Gibson, O. Samuelsson, P.O. Attman, C.S. Wang, and P. Alaupovic Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency Kidney International 61 1 2002 209 218
28. T.J. Lyons, A.J. Jenkins, D. Zheng, R.L. Klein, J.D. Otvos, and Y. Yu Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Associations with carotid intima-media thickness Diabetic Medicine 23 9 2006 955 966
29. T.J. Lyons, A.J. Jenkins, D. Zheng, D.T. Lackland, D. McGee, and W.T. Garvey Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort Investigative Ophthalmology & Visual Science 45 3 2004 910 918
30. W. Marz, M. Trommlitz, and W. Gross Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I Journal of Clinical Chemistry and Clinical Biochemistry 26 9 1988 573 578
31. M.E. Molitch Management of dyslipidemias in patients with diabetes and chronic kidney disease Clinical Journal of the American Society of Nephrology 1 5 2006 1090 1099
32. M.E. Molitch, M. Steffes, W. Sun, B. Rutledge, P. Cleary, and I.H. de Boer Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study Diabetes Care 33 7 2010 1536 1543
33. H. Mulec, S.A. Johnsen, O. Wiklund, and S. Bjorck Cholesterol: A renal risk factor in diabetic nephropathy? American Journal of Kidney Diseases 22 1 1993 196 201
34. C.L. Nelson, C.S. Karschimkus, G. Dragicevic, D.K. Packham, A.M. Wilson, and D. O'Neal Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function Nephrology, Dialysis, Transplantation 20 11 2005 2420 2426
35. E.M. Ooi, P.H. Barrett, D.C. Chan, and G.F. Watts Apolipoprotein C-III: Understanding an emerging cardiovascular risk factor Clinical Science (London, England) 114 10 2008 611 624
36. T.J. Orchard, Y.F. Chang, R.E. Ferrell, N. Petro, and D.E. Ellis Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study Kidney International 62 3 2002 963 970
37. B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, and A.S. Krolewski Regression of microalbuminuria in type 1 diabetes The New England Journal of Medicine 348 23 2003 2285 2293
38. O. Samuelsson, P.O. Attman, C. Knight-Gibson, R. Larsson, H. Mulec, and L. Weiss Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency Journal of the American Society of Nephrology 9 8 1998 1482 1488
39. S.D. Sibley, J.E. Hokanson, M.W. Steffes, J.Q. Purnell, S.M. Marcovina, and P.A. Cleary Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes Diabetes Care 22 7 1999 1165 1170
40. S.D. Sibley, W. Thomas, I. de Boer, J.D. Brunzell, and M.W. Steffes Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: Role of central obesity American Journal of Kidney Diseases 47 2 2006 223 232
41. Standards of medical care in diabetes - 2011 Diabetes Care 34 Suppl 1 2011 S11 S61
42. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus The New England Journal of Medicine 329 14 1993 977 986
43. L.M. Thorn, C. Forsblom, J. Waden, M. Saraheimo, N. Tolonen, and K. Hietala Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes Diabetes Care 32 5 2009 950 952
44. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
45. E. Werle, W. Fiehn, and C. Hasslacher Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients Diabetes Care 21 6 1998 994 998
46. K.V. Williams, J.R. Erbey, D. Becker, S. Arslanian, and T.J. Orchard Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49 4 2000 626 632
47. T. Wu, K.C. McGrath, and A.K. Death Cardiovascular disease in diabetic nephropathy patients: Cell adhesion molecules as potential markers? Vascular Health and Risk Management 1 4 2005 309 316
48. S. Yamamoto, P.G. Yancey, T.A. Ikizler, W.G. Jerome, R. Kaseda, and B. Cox Dysfunctional high-density lipoprotein in patients on chronic hemodialysis Journal of the American College of Cardiology 60 23 2012 2372 2379